| 產(chǎn)品編號 | BIO0018SM |
| 英文名稱 | Anti-human CTLA-4 / CD152 (Ipilimumab Biosimilar) |
| 中文名稱 | |
| 抗體來源 | |
| 克隆類型 | Monoclonal |
| 克 隆 號 | |
| 交叉反應(yīng) | Human,Cynomolgus |
| 產(chǎn)品應(yīng)用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 145.38 kDa |
| 檢測分子量 | |
| 性 狀 | Lyophilized |
| 亞 型 | Human IgG1 |
| 純化方法 | Protein A |
| 保存條件 | For long term storage, the produce should be stored at -20°C or lower. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | |
| 產(chǎn)品圖片 |
Ipilimumab inhibited the tumor growth of MC38 on huCTLA-4 mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 99.3% at 0.88 mpk at D37.
Human CTLA-4 & Human PD-1 CHO-K cells were stained with Anti-CTLA-4 / CD152 Reference Antibody (ipilimumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.2270 ug/mL.
The purity of Anti-CTLA-4 / CD152 Reference Antibody (ipilimumab) is 99.37%, determined by SEC-HPLC.
Anti-CTLA-4 / CD152 Reference Antibody (ipilimumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
|
